Tidal Investments LLC Sells 24,386 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Tidal Investments cut its Alnylam Pharmaceuticals stake by 42.1% in the second quarter, selling 24,386 shares and retaining 33,541 shares valued at approximately $10.1 million. Institutional investors and hedge funds collectively own 92.97% of ALNY.
• Analysts reduced their price targets, though the stock maintains a consensus “Moderate Buy” rating with an average target of $376.67. Targets now range from $256 at Wells Fargo to $350 at Oppenheimer.
• Alnylam reported quarterly EPS of $1.84, beating estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion. Shares opened at $248.68, well below their 52-week high of $495.55.

Tidal Investments LLC lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 42.1% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 33,541 shares of the biopharmaceutical company's stock after selling 24,386 shares during the quarter. Tidal Investments LLC's holdings in Alnylam Pharmaceuticals were worth $10,097,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ALNY. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter worth $29,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. Golden State Wealth Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Finally, Manchester Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 72 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wells Fargo & Company lowered their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an "equal weight" rating for the company in a research note on Friday, August 14th. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating for the company in a research report on Friday, July 31st. Stifel Nicolaus cut their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a "buy" rating on the stock in a research note on Friday, July 31st. Oppenheimer reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $376.67.

Alnylam Pharmaceuticals Trading Up 0.5%

Shares of Alnylam Pharmaceuticals stock opened at $248.68 on Friday. The firm has a market cap of $33.28 billion, a PE ratio of 46.22 and a beta of 0.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The stock has a fifty day moving average price of $254.43 and a 200-day moving average price of $288.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts' consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the firm earned ($0.51) EPS. The company's revenue was up 66.9% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.